2018 News

2018 News

April 9, 2018

Morphotek Announces Agreement to License its Proprietary Eribulin-Linker Payload to Bliss Biopharmaceutical Co., LTD. for Development of A Therapeutic Antibody-Drug Conjugate (ADC)*
Read More

January 24, 2018

Morphotek to Present Poster on CA125 Suppression of Humoral Immune Responses of Antibodies at the Upcoming ASCO-SITC Clinical Immuno-Oncology Symposium
Read More

January 10, 2018

Morphotek Announces FDA Acceptance of Investigational New Drug Application for Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202
Read More

News & Events > News Archive > 2018 News